H3D to boost drug discovery research capacity at University of Limpopo


The University of Cape Town’s (UCT) Drug Discovery and Development Centre (H3D) has partnered with the University of Limpopo (UL) on a project to boost drug discovery research capacity at this historically disadvantaged institution (HDI).

The project titled “TB Drug Discovery Hit to Lead Optimization” aims to contribute to finding solutions for Africa’s tuberculosis (TB) epidemic through cutting-edge research. It will expand on existing work focusing on the synthesis of novel compounds active against Mycobacterium tuberculosis (M. tb), the causative agent for TB.

UL’s Professor Winston Nxumalo has been appointed as the principal investigator on the project, while H3D, led by UCT’s Professor Kelly Chibale, will be offering support in the form of training, mentoring and access to infrastructure, including TB biology and drug metabolism and pharmacokinetics screening assays.

Aligning strongly with the South African Medical Research Council’s (SAMRC) capacity-building agenda, the project has been named as a beneficiary of the Strategic Health Innovation Partnerships (SHIP) programme.

Read more about this news here.

Related articles

Recent articles